Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :2210
Small font sizeDefault font sizeIncrease font size
Navigate here
Resource links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (821 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)  

  In this article
 »  References

 Article Access Statistics
    PDF Downloaded242    
    Comments [Add]    
    Cited by others 4    

Recommend this journal


  Table of Contents  
Year : 2011  |  Volume : 48  |  Issue : 4  |  Page : 514-515

Which non-small-cell lung cancer patients achieve long-term survival?

Department of Medical Oncology, National Institute of Oncology, Morocco

Date of Web Publication25-Jan-2012

Correspondence Address:
N Ahbeddou
Department of Medical Oncology, National Institute of Oncology
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.92248

Rights and Permissions

How to cite this article:
Ahbeddou N, Fetohi M, Boutayeb S, Errihani H. Which non-small-cell lung cancer patients achieve long-term survival?. Indian J Cancer 2011;48:514-5

How to cite this URL:
Ahbeddou N, Fetohi M, Boutayeb S, Errihani H. Which non-small-cell lung cancer patients achieve long-term survival?. Indian J Cancer [serial online] 2011 [cited 2022 Jul 4];48:514-5. Available from:


Lung cancer is the first cause of cancer death worldwide. The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) remains poor. Recent phase III trials demonstrated median survivals from 8 to 10 months and only 4-8% of patients have been reported to survive more than 5 years. [1],[2] We write to you to share an unexpected and hopeful experience: A NSCLC patient with an advanced disease, now in 12-year remission.

Mr. E, a 58-year-old man, consulted us in June 1998 because of chest pain and weight loss. The patient was a heavy smoker (20 pack year). He had a good performance status and no significant medical history. Thoracic computed tomography (CT) revealed an upper lobe mass of 9 × 7.6 cm in the right lung associated with mediastinal lymphadenopathy. Fibroscopic bronchoscopy did not show any neoplastic lesion. A CT-guided biopsy was performed and the histopathological report showed features consistent with squamous carcinoma. Immunohistochemical staining was positive for cytokeratin 7/5/6 while cytokeratin 20 was negative. This profile assessed the diagnosis of stage III NSCLC (T3, N1, M0). He was not a suitable candidate for surgery. Chemoradiotherapy was performed (64 Gy in 32 fractions in 4 weeks) with three cycles of cisplatin and vinorelbin. A CT after the end of treatment showed a partial response with a continued benefice at 1-year control. Twelve years later, the patient is asymptomatic with a good performance status, good quality of life, and no evidence of recurrence.

Such unexpected clinical remission and long-term survival is extremely rare. Several reports in the literature tried to establish prognostic models. Some suggested that good performance status, weight loss, adenocarcinoma histotype, resectable N2, T3N0, single-site distant metastasis, and EGFR-TKI therapy play an important role in the long-term survival.[1] ,[2]

A systematic overview of the literature suggested additional factors to refine the accuracy of prognosis: age, number of sites involved, hemoglobin, LDH, and albumin.[3]

We should keep in mind such cases when discussing with patients about fears, hopes, and realistic expectations. More researches are required to fully assess more accurate predictors of the outcome. Further prognostic markers as EGFR mutation should be investigated. New promising factors include proliferation markers, Ki-67, NSE, TPA, and coagulation factors. [3]

 » References Top

1.Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: Which advanced stage non small cell lung cancer patients attain long-term survival? Cancer 2010;116:1518-25.   Back to cited text no. 1
2.Kaira K, Takahashi T, Murakami H, Tsuya A, Nakamura Ynone , Naito Tnone ,et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer 2010;67:120-3.  Back to cited text no. 2
3.Brundage MD, Davies D, Mackillop WJ. Prognostic Factors in Non-small Cell Lung Cancer: A Decade of Progress. Chest 2002;122:107-57.  Back to cited text no. 3

This article has been cited by
1 Two-step progression of varenicline-induced autoimmune hepatitis
Mitsuru Sakakibara,Kazuyoshi Ohkawa,Takatoshi Nawa,Yutaro Abe,Akira Kusakabe,Toshihiro Imai,Kazuhiro Katayama
Clinical Journal of Gastroenterology. 2018; 11(3): 184
[Pubmed] | [DOI]
2 Is there a subgroup of long-term evolution among patients with advanced lung cancer?: Hints from the analysis of survival curves from cancer registry data
Lizet Sanchez,Patricia Lorenzo-Luaces,Carmen Viada,Yaima Galan,Javier Ballesteros,Tania Crombet,Agustin Lage
BMC Cancer. 2014; 14(1)
[Pubmed] | [DOI]
3 Application of urine proteomics for biomarker discovery in drug-induced liver injury
Rachel P. L. van Swelm,Cornelis Kramers,Rosalinde Masereeuw,Frans G. M. Russel
Critical Reviews in Toxicology. 2014; : 1
[Pubmed] | [DOI]
4 Post-transplantation encapsulating peritoneal sclerosis in a pediatric patient
Nicole da Silva,Sofia Rocha,Liliana Rocha,Sameiro Faria,Teresa Costa,Conceição Mota
Pediatric Nephrology. 2012; 27(9): 1583
[Pubmed] | [DOI]


Print this article  Email this article


  Site Map | What's new | Copyright and Disclaimer | Privacy Notice
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow